EUROFINS SCIENTIFIC (ERF.PA) 61.4 +0.16 (+0.26%)
61.4 +0.16 (+0.26%)
FR0014000MR3 - Common Stock
Fundamental Rating
Overall ERF gets a fundamental rating of 3 out of 10. We evaluated ERF against 7 industry peers in the Life Sciences Tools & Services industry. ERF has a bad profitability rating. Also its financial health evaluation is rather negative. ERF has a correct valuation and a medium growth rate.
Profitability
Profitability Rating
ERF has a Return On Assets of 6.26%. This is below the industry average of 9.72%. 80% of the industry peers outperform ERF.
ERF's Return On Equity of 13.68% is worse than the rest of the industry. The industry average Return On Equity is 22.19%.
ERF's Profit Margin of 9.37% is worse than the rest of the industry. The industry average Profit Margin is 16.24%.
ERF has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of ERF.
VS Industry
ROA (6.26%) VS Industry: 20% outperformed.
2.87
21.58
ROE (13.68%) VS Industry: 40% outperformed.
7.73
34.07
Profit Margin (9.37%) VS Industry: 25% outperformed.
5.29
20.63
Valuation
Valuation Rating
ERF's low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
Compared to an average industry price book ratio of 2.99, ERF is valued rather cheaply
Compared to an average Enterprise Value to EBITDA ratio of 21.20, ERF is valued rather cheaply. On top of this, ERF has a better ratio than 100% of the companies listed in the same industry.
With a Price/Earnings Ratio of 19.19, ERF is valued on the expensive side.
Compared to an average industry Price/Earning Ratio of 19.98, ERF is valued in line with its industry peers.
The Forward Price/Earnings Ratio of 18.71 indicates a rather expensive current valuation of ERF.
When comparing the current price to the book value of ERF, we can conclude it is valued correctly. It is trading at 2.52 times its book value.
VS Industry
Price/Earnings (19.19) VS Industry: 60% outperformed.
41.94
7.07
Price/Book (2.52) VS Industry: 66% outperformed.
13.80
1.24
Enterprise Value/ EBITDA (8.25) VS Industry: 100% outperformed.
539.50
8.25
Growth
Growth Rating
The Earnings Per Share has been growing by 35.72% on average over the past 5 years. This is a very strong growth
ERF shows a strong growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 21.50% yearly.
The Earnings Per Share is expected to decrease by -5.21% on average over the next 5 years.
Looking at the last year, ERF shows a small growth in Revenue. The Revenue has grown by 7.35% in the last year.
Based on estimates for the next 5 years, ERF will show a small growth in Revenue. The Revenue will grow by 1.83% on average per year.
ERF shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -29.82%.
When comparing the EPS growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | 35.72% | 57.76% | -29.82% | -22.57% | -15.98% | -8.43% | -5.21% |
| Revenue | 21.5% | 21.12% | 7.35% | 4.61% | 1.76% | 3.58% | 1.83% |
Health
Health Rating
A Current Ratio of 1.33 indicates that ERF should not have too much problems paying its short term obligations.
A Quick Ratio of 1.25 indicates that ERF should not have too much problems paying its short term obligations.
ERF has a Quick Ratio comparable to the industry average, which is at 1.25.
ERF has an Altman-Z score of 2.92. This is not the best score and indicates that ERF is in the grey zone with still only limited risk for bankruptcy at the moment.
When comparing the Current Ratio of ERF to the average industry Current Ratio of 1.49, ERF is less able to pay its short term obligations than its industry peers.
Compared to an average industry Debt to Equity Ratio of 0.48, ERF is requires more financing than its industry peers. 84% of its industry peers have a better Debt to Equity Ratio.
Compared to an average industry Altman-Z score of 4.32, ERF is in worse financial state than most of its industry peers. 84% of its industry peers have a better Altman-Z score.
ERF has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of ERF.
VS Industry
Debt/Equity (0.66) VS Industry: 16% outperformed.
1.00
0.00
Quick Ratio (1.25) VS Industry: 50% outperformed.
0.45
19.50
Current Ratio (1.33) VS Industry: 33% outperformed.
0.74
19.50
Altman-Z (2.92) VS Industry: 16% outperformed.
1.69
26.71
Dividend
Dividend Rating
Compared to an average industry Dividend Yield of 1.49, ERF pays a bit more dividend than its industry peers.
On average, the dividend of ERF grows each year by 51.43%, which is quite nice.
With a Yearly Dividend Yield of 1.49%, ERF has a reasonable but not impressive dividend return.
With a Dividend Yield of 1.49, ERF pays less dividend than the S&P500 average, which is at 2.60.
The Dividend Rate of ERF has been growing, while earnings will be declining. This means the dividend growth is most likely not sustainable.
The earnings of ERF are negative and hence is the payout ratio. ERF will probably not be able to sustain this dividend level.
VS Industry
Dividend Yield (1.49%) VS Industry: 66% outperformed.
0.40
1.82
EUROFINS SCIENTIFIC61.4
EPA:ERF (3/29/2023, 9:52:21 AM)+0.16 (+0.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap11.82B
Analysts68.42
Price Target73.51 (19.72%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.49% |
Dividend Growth(5Y)51.43%
DP-0.06%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
PT rev (1m)-8.11%
PT rev (3m)-12.52%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-5.9%
EPS NY rev (3m)-5.9%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.13%
Revenue NY rev (3m)-0.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.19 | ||
| Fwd PE | 18.71 | ||
| P/S | 1.72 | ||
| P/FCF | 17.3 | ||
| P/OCF | 9.31 | ||
| P/B | 2.52 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.25 |
EPS(TTM)3.2
EY5.21%
EPS(NY)3.28
Fwd EY5.34%
FCF(TTM)3.55
FCFY5.78%
OCF(TTM)6.59
OCFY10.74%
SpS35.62
BVpS24.4
TBVpS-3.78
PEG (NY)N/A
PEG (5Y)0.54
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.26% | ||
| ROE | 13.68% | ||
| ROIC | 11.73% | ||
| ROICexc | 12.86% | ||
| ROICexgc | 46.3% | ||
| OM | 18.39% | ||
| PM | 9.37% | ||
| GM | 25.13% |
ROICexgc(3y)42.91%
ROICexcg growth 3Y20.47%
ROICexcg growth 5Y4.83%
ROICexc(3y)12.04%
ROICexc growth 3Y31.18%
ROICexc growth 5Y8.68%
OM growth 3Y16.76%
OM growth 5Y9.23%
PM growth 3Y33.94%
PM growth 5Y15.35%
GM growth 3Y14.14%
GM growth 5Y8.41%
F-Score3
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 4.9 | ||
| Debt/EBITDA | 1.91 | ||
| Cap/Depr | 120.5% | ||
| Profit Quality | 106.32% | ||
| Current Ratio | 1.33 | ||
| Quick Ratio | 1.25 | ||
| Altman-Z | 2.92 |
F-Score3
WACC6.74%
ROIC/WACC6.87
Cap/Depr(3y)82.57%
Cap/Depr(5y)96.41%
Profit Quality(3y)159.26%
Profit Quality(5y)133.79%
Growth
EPS 1Y-29.82%
EPS 3Y57.76%
EPS 5Y35.72%
EPS growth Q2Q-26.4%
EPS Next Y-22.57%
EPS Next 2Y-15.98%
EPS Next 3Y-8.43%
EPS Next 5Y-5.21%
Revenue growth 1Y7.35%
Revenue growth 3Y21.12%
Revenue growth 5Y21.5%
Revenue growth Q2Q4.25%
Revenue Next Year4.61%
Revenue Next 2Y1.76%
Revenue Next 3Y3.58%
Revenue Next 5Y1.83%
EBIT growth 1Y-17.36%
EBIT growth 3Y41.42%
EBIT growth 5Y32.72%
EBIT Next Year17.93%
EBIT Next 3Y5.94%
EBIT Next 5Y6.11%
FCF growth 1Y50.16%
FCF growth 3Y76.72%
FCF growth 5Y41.9%
OCF growth 1Y42.52%
OCF growth 3Y40.54%
OCF growth 5Y32.35%
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the EuroNext
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the EuroNext
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the EuroNext
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the EuroNext